Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 36, Issue 1, 1995, Pages 45-52

  Houghton, Peter J ^a   Cheshire, Pamela J ^a   Hallman II, James D ^a   Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Carzelesin; Drug resistance; Human tumor xenrografts; Rhabdomyosarcoma

Indexed keywords

ALKYLATING AGENT; CARZELESIN; CYCLOPROPYLPYRROLOINDOLE DERIVAIVE; MELPHALAN; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER SIZE; CHILDHOOD CANCER; COLON ADENOCARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; XENOGRAFT;

ADENOCARCINOMA; ADOLESCENT; ADULT; ANIMAL; ANTINEOPLASTIC AGENTS; BENZOFURANS; CHILD; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; INDOLES; LETHAL DOSE 50; MALE; MICE; MICE, INBRED CBA; RHABDOMYOSARCOMA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0028919512     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00685731     Document Type: Article

References (16)

1. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard
2. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino]-1-piperidino)-carbonyloxycamptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
3. Evaluation of a novel bis-naphthalimide anticancer agent, DMP840, against human xenografts derived from adult, juvenile, and pediatric cancers
4. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
5. Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy
6. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma
7. Drug sensitivity and resistance in the xenograft model
8. The suitability and use of human tumor xenografts
9. Evaluation of N-(5-indanylsulfonyl)- N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma
10. Rhabdomyosarcoma, from the laboratory to the clinic
11. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice
12. Coupling of cyclopropapyrroloindole (CPI) derivatives. The preparation of CC-1065, ent-CC-1065, and analogs
13. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue
14. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065
15. Stereo electronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065
16. Resistance of CHO cells expressing P-glycoprotein to cyclopropylpyrroloindole (CPI) alkylating agents